MedTrace Logo

Is ESWT Better in Plantar Fasciitis Treatment?

NCT05647291 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-12-16

No results posted yet for this study

Summary

It was aimed to compare the pain and functional results of ESWT, kinesiotherapy and corticosteroid injection in patients with treatment-resistant plantar fasciitis.

Conditions

  • Plantar Fascitis

Interventions

DEVICE

extracorporeal Shock wave therapy

Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week, for two weeks, adding up to a total of 4 sessions.

DRUG

Corticosteroid injection

40mg/1ml methylprednisolone, two sessions once a week

DEVICE

Kinesiotaping

The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends. Once a week, three times

Sponsors & Collaborators

  • Sanliurfa Education and Research Hospital

    collaborator OTHER_GOV

  • Harran University

    lead OTHER

Principal Investigators

  • Özlem Orhan · Department of Orthopaedics and Traumatology, Harran University Medicine Faculty, Şanlıurfa, Turkey

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2022-04-17
Completion
2022-07-28

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05647291 on ClinicalTrials.gov